Decreasing the adverse effects of cancer therapy: An NCI workshopon the preclinical development of radiation injury mitigators/protectors

Radiation Research

Volumn 176, Issue 5, 2011, Pages 688-691

  Ryan, Julie L ^a   Krishnan, Sunil ^b   Movsas, Benjamin ^c   Coleman, C Norman ^d   Vikram, Bhadrasain ^d   Yoo, Stephen S ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; RADIOPROTECTIVE AGENT;

CANCER RADIOTHERAPY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; HUMAN; MAXIMUM TOLERATED DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; MAXIMUM TOLERATED DOSE; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; UNITED STATES;

EID: 80155193785     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2704.1     Document Type: Review

References (10)

1. Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 2004; 162:711-28. (Pubitemid 39552901)
2. Patt HM, Mayer SH, Straube RL, Jackson EM. Radiation dose reduction by cysteine. J Cell Physiol 1953; 42:327-41.
3. Cassatt DR, Kaminski JM, Hatchett RJ, DiCarlo AL, Benjamin JM, Maidment BW. Medical countermeasures against nuclear threats: radionuclide decorporation agents. Radiat Res 2008; 170:540-8.
4. DiCarlo AL, Hatchett RJ, Kaminski JM, Ledney GD, Pellmar TC, Okunieff P, et al. Medical countermeasures for radiation combined injury: radiation with burn, blast, trauma and/or sepsis. report of an NIAID Workshop, March 26-27, 2007. Radiat Res 2008; 169:712-21. (Pubitemid 351793461)
5. Dumont F, Le Roux A, Bischoff P. Radiation countermeasure agents: an update. Expert Opin Ther Pat 2010; 20:73-101.
6. Hafer N, Cassatt D, DiCarlo A, Ramakrishnan N, Kaminski J, Norman MK, et al. NIAID/NIH Radiation/Nuclear Medical Countermeasures Product Research and Development Program. Health Phys 2010; 98:903-5.
7. Brizel DM, Overgaard J. Does amifostine have a role in chemoradiation treatment? Lancet Oncol 2003; 4:378-81.
8. Movsas B, Vikram B, Hauer-Jensen M, Moulder J, Basch E, Brown SL, et al. Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res 2011; 17:222-8.
9. F.D.A. Guidance for Industry: S1B Testing for Carcinogenicity of Pharmaceuticals. Rockville (MD): July 1997; Available from: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074916.pdf.
10. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2009; 85:217-21.